From: Hypertension, antihypertensive drugs, and age at onset of Huntington’s disease
Exposure | N SNPs | Heterogeneity analysis | Pleiotropy analysis | ||||||
---|---|---|---|---|---|---|---|---|---|
Method | Q | Degree of freedom | P | Method | Egger intercept | SE | P | ||
SBP | 435 | MR Egger | 435.9 | 433 | 0.452 | MR Egger intercept | -0.004 | 0.016 | 0.793 |
IVW | 436.0 | 434 | 0.464 | MR-PRESSO Global test | 0.462 | ||||
DBP | 439 | MR Egger | 437.3 | 437 | 0.487 | MR Egger intercept | 0.013 | 0.015 | 0.386 |
IVW | 438.1 | 438 | 0.490 | MR-PRESSO Global test | 0.489 | ||||
BB (LD threshold, r2 < 0.4) | 8 | MR Egger | 2.6 | 6 | 0.856 | MR Egger intercept | -0.129 | 0.193 | 0.528 |
IVW | 3.1 | 7 | 0.879 | MR-PRESSO Global test | 0.889 | ||||
CCB (LD threshold, r2 < 0.4) | 58 | MR Egger | 52.9 | 56 | 0.594 | MR Egger intercept | 0.065 | 0.051 | 0.207 |
IVW | 54.5 | 57 | 0.569 | MR-PRESSO Global test | 0.616 | ||||
BB(LD threshold, r2 < 0.2) | 7 | MR Egger | 2.0 | 5 | 0.852 | MR Egger intercept | -0.115 | 0.194 | 0.580 |
IVW | 2.3 | 6 | 0.887 | MR-PRESSO Global test | 0.884 | ||||
CCB(LD threshold, r2 < 0.2) | 30 | MR Egger | 33.0 | 28 | 0.236 | MR Egger intercept | 0.017 | 0.072 | 0.813 |
IVW | 33.1 | 29 | 0.276 | MR-PRESSO Global test | 0.303 |